Search results
Showing 1 to 7 of 7 results for lorlatinib
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.
Show all sections
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.
Past technology appraisal appeals and decisions
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.
Discontinued Reference number: GID-TA11289
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
This guidance has been updated and replaced by NICE technology appraisal guidance 1103.